Literature DB >> 3092655

Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa.

C J Hawkey, G Simpson, K W Somerville.   

Abstract

Enprostil's ability to protect human gastric mucosa against aspirin-induced damage was investigated in a controlled study. Damage was assessed as blood loss into gastric washings measured spectrophotometrically using orthotolidine in the presence of hydrogen peroxide. Phenol red was used to correct for recovery rates. Five doses of aspirin, 600 mg, given over 48 hours increased blood loss ninefold compared with placebo. Administration of enprostil 35 micrograms twenty minutes before each dose of aspirin halved this blood loss. After enprostil administration, the pH of both aspirated gastric juice and washings was significantly elevated, suggesting that an antisecretory dose had been used. Increased losses of phenol red occurred following both aspirin and enprostil administration, suggesting enhanced gastric emptying or possible absorption of phenol red as a result of aspirin damage. Side effects related mainly to the alimentary system were associated with enprostil treatment. Enprostil reduced aspirin-induced mucosal blood loss but the mechanism is unclear.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092655     DOI: 10.1016/s0002-9343(86)80011-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Inhibitory action of enprostil (4,5-dehydro-16-phenoxy-17,18,19,20-tetranor-PGE2) on tetra-gastrin stimulated acid secretion in human subjects.

Authors:  M Moriga; M Aono; H Narusawa; Y Kohli; T Kato; G Kajiyama; M Inoue; A Miyoshi
Journal:  Gastroenterol Jpn       Date:  1989-04

3.  Effect of enprostil on amphibian gastroduodenal and human gastric bicarbonate secretion.

Authors:  C J Shorrock; L C Gibbons; W D Rees
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

4.  Failure of ethamsylate to reduce aspirin-induced gastric mucosal bleeding in humans.

Authors:  T K Daneshmend; A G Stein; N K Bhaskar; C J Hawkey
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  A US multicenter study of enprostil 35 micrograms twice daily for treatment of prepyloric, pyloric channel, and duodenal bulb ulcers. Enprostil Study Group.

Authors:  T T Schubert; J A Frizzell; P B Meier; R I Cano; K E Schwartz
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

6.  Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding.

Authors:  P J Prichard; T J Poniatowska; J E Willars; A T Ravenscroft; C J Hawkey
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

7.  Prostaglandins in peptic ulcer disease. An overview of current status and future directions.

Authors:  S J Sontag
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

8.  Gastric mucosal protection with selective inhibition of thromboxane synthesis.

Authors:  R P Walt; R T Kemp; B Filipowicz; J G Davies; N K Bhaskar; C J Hawkey
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

Review 9.  Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.

Authors:  Martin W James; Christopher J Hawkey
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

10.  Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin.

Authors:  P J Prichard; G K Kitchingman; R P Walt; T K Daneshmend; C J Hawkey
Journal:  BMJ       Date:  1989-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.